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Background: In Australia, 10-16% acute hospital admissions is related to medication. Home 
medication review is offered to patients using multiple medications, those with narrow therapeutic-
index. It is also recommended for people with recent changes to their medication, who were recently 
discharged from hospital or who have difficulties with their medication.  
Objectives: The aim of this study was to identify issues that arise during the process and explore the 
barriers experienced when changes to patient medication regimen are recommended.  
Setting: All interviews were conducted in Australia in patients’ homes in accordance with the 
appropriate guidelines. 
Method: This study used historical data from past consultations conducted in Australia.  
The audit was approved by the University of Wolverhampton Human Research Ethics Committee. It 
is based on anonymised historical data.  
Main outcome measure: This audit explored improvement in patient health outcomes and service 
satisfaction 
Results: Out of 28 home medication reviews, only two occasions were the pharmacist’s 
recommendations, actioned. On eight occasions, the clinic receptionist acknowledged the receipt of 
the report but it was not actioned and on 18 occasions no response was received from the doctor or 
the clinic receptionist. 
Conclusion: This audit suggests four important areas in the home medication review process require 
review; the initiation of home medication review, the requirement for diagnostics and recent history 
to be provided prior to the review, the need to for discussion between the doctors and pharmacists 
around the recommendations and whether they will be actioned or the reason if they will not be 
actioned.  
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Medication-related hospitalizations are frequent, estimated to 
account for about 10 - 16% of all admissionsto medical 
departments, with most of them judged to be preventable 
(Kongkaew, 2008; Mathews et al., 1988). Also; patient 
adherence to their medication regimen has been shown to be 
lower than 50% (Mathews, 1988). This suboptimal use of 
medication reduces the patients’ quality of life and is costly for 
society.  
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Globally, pharmacist-ledmedication management review is a 
widely-recognised concept to help address this; however, the 
way it is conducted varies between countries. Many countries 
perform this function from within ahospital or community 
pharmacy, whereas in Australia home medication review 
(HMR) accredited pharmacists can outreach to the patients in 
their home or in residential accommodation. This should place 
Australia at an advantage in gaining benefits. The Australian 
Government initiated the HMR program, managed by the 
Pharmacy Guild of Australia and funded by Medicare. For a 
pharmacist to conduct HMRs, they must successfully complete 
one of the approved credentialing programs provided by the 
Australian Association of Consultant Pharmacists, or the 
Society of Hospital Pharmacists of Australia. 
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The HMR process involves the patient, their local general 
medical practice and pharmacists. Where the local pharmacist 
is not accredited, an accredited pharmacist can be chosen by 
the patient or their local community pharmacy to undertake the 
review. HMR is an outreach health service delivered at the 
patient’s domicile. The doctorrefers the patient to a 
pharmacist; who conducts an interview, usuallywhere the 
patient lives, unless there is any safety or access concerns 
(which happens occasionally). The pharmacist performs the 
HMR and identifies medication-related problems/issues to be 
resolved. A report is written from the pharmacist to the doctor 
suggesting actions which, based upon the information 
available, the pharmacist believesare appropriate. In theory, the 
doctor completes the process by informing Medicare of the 
receipt of the pharmacist’s report and reviewing and actioning 
appropriate suggestions. HMR is a formal process, where both 
the doctor and pharmacist are remunerated from public funds.  
 
HMR is recommended for any patients taking five or more 
medications, have recently spent time in hospital, are 
concerned or confused about their medications or are non-
adherent to their medication regimen (Morrissey et al., 2015). 
While the process is intended to be a complete cycle, 
commencing from the doctor’s clinic and completed there, it is 
disjointed by problems arising infour areas: 
 
 Point of referral to initiate the HMR process. On many 
occasions patients or pharmacists formally request the 
referral letter from the doctor, to addressa patient’s 
expressed need, or as identified by the pharmacist.In 
practice, it may often take several weeks even to several 
months before a referral letter is raised, if it is raised at 
all (Morrissey et al., 2015; Rigby, 2010; Rigby, 2011; 
Harris et al., 2011; Tordoff et al., 2012; Morrissey, 
2015; Gerard et al., 2012). The referral. The referral is 
frequently received by the pharmacist with only 
minimal supporting clinical information, leading to 
additional time being lost while the pharmacist requests 
additional information from the doctor’s clinic.  Further 
the system places no obligation on the doctor to provide 
this and it may not be supplied. Yet, it is practically 
impossible for a pharmacist to make meaningful 
comments on the prescribed regimen without this 
information.  
 The completed report. When an electronic copy and the 
written report arereturned to the doctor’s clinic, it may 
be several weeks before acknowledgement is received. 
Reports (and personal experience) show that this 
frequently occurs only when the pharmacist callsthe 
practice to request it,and then receives only a verbal 
confirmation that the report was received.  
 Post-submission of the report to the general medical 
practitioner (GP), the recommendations should be 
actioned.  It would be a common courtesy and help in 
future reporting if any reasons for not actioning the 
recommendations were provided to the patient and/or 
the pharmacist but currently there is no obligation on 
the GP to do this. 
 
The author had a conversation where a GP reported that an 
HMR received was ‘useless’ because the pharmacist had 
completely ignored that the patient had ‘xx disease’; the doctor 
was asked whether that information had ever been relayed to 
the pharmacist or how the pharmacist would have had any 
other way of knowing this? Clearly there are communication 
issues to address.   
This audit aimedto analyse some of the findings from 
pharmacists’ reviews and the recommendations made, to 




The aim of this study was to identify issues that arise during 
the process and explore the barriers experienced when changes 




The audit was approved by the University of Wolverhampton 
Human Research Ethics Committee. It is based on anonymised 
historical data. Home medication review interviews were 




The study was conducted on pooled, anonymised historical 
data from HMR reviews undertaken by the first author, who is 
anHMR accredited consultant pharmacist, with a PhDthat 
studied pharmacist involvement in chronic disease 
management in primary care.The sample consists of all 
patients referred to the author during a consecutive recent 12-
month period (dates not stated to maintain patient and doctor 
identities confidential). Ethics clearance to use the historical 
data was obtained from the University of Wolverhampton 
Ethics in Human Research Committee 
(LSEC/2016/17/HM/103). The interviews had been conducted 
on referral from the patient’s doctor and patients were aware in 
advance of the pharmacist’s visit. The interviews were 
conducted in accordance with the home medication review 
guidelines of the Australian Association of Consultant 
Pharmacists and the Pharmaceutical Society of Australia 
(Morrissey et al., 2015). 
 
This study reviewed in detail the reports and recommendations 
from 28 historical HMR’s, and all outcome information 





All data included was frompatients who had multiple 
comorbidities of chronic diseases. Of the 28 patients 32% were 
men (n=9) and 68% women (n=19). The largest group of the 
men (n=4) were in the 50 to 59 yearsage group and majority of 




Figure 1. Population age and gender 
Living conditions were considered to establish if the patient 
self-managed their medication or had a carer (Table 1).   
 
Table 1. Social status of living 
 
Social status Number of patients  
Living with* Male Female 
A 0 5 
FC 0 1 
FC 0 1 
FC 0 1 
FC 1 0 
FC 0 6 
FC 0 1 
FC 0 1 
FC 2 1 
FC 5 0 
FC 2 0 
                  * Living with family/carer (FC) or lives alone (A).  
 
The group included nine current smokers andeight ex-smokers. 
Five patients reported using Kava (Piper methysticum) on a 
regular basis whilenine reported consuming more than two 
standard alcoholicdrinks a day (Figure 2). In 2003, the Food 
and Drug Administration issues a warning as a result of 11 
cases of hepatic failure leading to liver transplants and four 




*Alcohol: nil (0), one drink (1), two drinks (2) 
**Recreational drugs: Kava (K), Others (O), Never-used illicit drugs(N) 
***Tobacco Smoking: Smoker (S), Never-smoked (NS), EX-smoker (EX-S) 
 
Figure 2. Tobacco smoking, illicit drug use  
and alcohol daily intake 
 
One personwas in a wheel-chair (female), six were physically 
active (four females and two males) and 21 physically inactive 
(13 females and eight males). The most frequently used 
medications are shown in figure 3. All used medications are 




Figure 3.  Medications used by five patients or more 
The 28 patients had diagnoses for 37 different chronic 
conditions with an average of four per patient. Hypertension 
was the most common condition seen in 19 patients with 
comorbidity of other cardiovascular diseases such as heart 
failure in 11 patients. Both diabetes mellitus type 2 and 
gastroesophageal reflux disease (GORD) were seen in 10 
patients. Figure 4 illustrates the conditions seen in the sample 
population by frequency, in five patients or more, where table 




Figure 4. Conditions seen in the sample population by frequency 
 
Table 2. Conditions seen in less than five patients 
 
Medical conditions Frequency  
Alpha thalassaemia trait, Dandruff, Diabetic nephropathy, 
Hashimoto, Iron deficiency, Menopause, Nausea and 
vomiting, Peripheral neuropathy, Psoriatic arthritis, 
Restless leg syndrome, Stool incontinence, Ulcerative 
colitis 
1 
Alzheimer’s, COPD, Glaucoma, Gout, Prostate 
carcinoma, Recurrent UTI, Sinus, Urinary tract infection 
2 
Asthma, Dry mouth / Dysphagia, Inflammatory Bowel 
Disease 
3 
Diabetic retinopathy, Urinary incontinence, Osteoporosis 4 
 
HMR communication between doctors and pharmacists 
 
Examining the communication processes and the timeframe 
between referral, review undertaken, submissionof the report 
and the doctors’feedbackidentified major lapses of 
communication. For 68% of reports submitted, no 
acknowledgement was received. On 93% of reports no 
feedback received from the doctor and only 18% of reports 
received an acknowledgement of receipt from the clinic 




Figure 5. Communication between pharmacists and doctors 
during the HMR process 
 
The pharmacists’ reports were all submitted within 48 hours 
from the receipt of the referral (Figure 6). 
 
 
Figure 6. Time indicated on the HMR referral 
 
Appendix2 contains the full details of patients’ reasonsfor 
requesting HMR from their doctor compared to the 
pharmacist’s observations during the visit, together withthe 
doctors provided reasons for referring the patient for HMR.On 
only 11out of 28 occasions did the three aspects match. 
Regarding the reason for referral (Figure 7), there was average 
of four reasons given for referral per person. The most selected 
reason was number of medications and least reason selected 




Figure 7. Reasons for referral 
 
 
*BMI- body mass index, BP-blood pressure, HR-heart rate, HbA1c- glycated 
haemoglobin, BGL-blood glucose level, CrCl- creatinine clearance, eGFR- 
estimated Glomerular Filtration Rate, HDL- high density lipoprotein, LDL- low 
density lipoprotein, TGs- triglycerides, TSH- thyroid-stimulating hormone, Na- 
sodium, K- potassium, Mg- magnesium, Ca- calcium, INR- international 
normalized ratio, B12- vitamin B12. 
 
Figure 8. Diagnostics received by the pharmacist on point of 
referral or on request 
In 50% of cases, the pharmacist received no diagnostic 
information or investigation results until they were requested.  
However, once requested, sufficient information was supplied 
to make recommendations at the time of the interview. 
Creatinine clearance was calculated whenever possible and 
was used for six occasions where the estimated glomerular 
filtration rate (eGFR) value was not provided by the doctor. 
Figure 8 summarises the number of recommendations that 




Figure 9. Recommendations categories made by the pharmacist 
and included in the HMR report to the doctors 
 
The most critical recommendation madewasrequesting 
aninvestigation to eliminate lung cancer. Hearing nothing from 
the practice, after 4 weeks, the patient called an ambulance 
andat the hospital, was diagnosedwith advanced lung cancer. 
No responsehad been received from the doctors regarding the 
HMR report and the practice had taken no action.  The second 
serious referral, which both the pharmacist and the carer 
independently attempted to follow upwith the practice, was a 
patient who seemed to have sepsis and worsening cardiacand 
renal failure. Both the carer and the pharmacist made clear to 
the doctor that the patient had seriously deteriorated since last 
seen, but no response was received from the practice, and 





Whilst this sample was small (n=28), the issues identified are 
in line with those reported in other studies; the communication 
breakdown was also similar to that identified in number of 
studies (Rigby, 2011; Harris et al., 2011; Tordoff et al., 2012; 
Morrissey et al., 2015; Gerard et al., 2012). The current 
Australian concept of HMR appears sound, but in reality, the 
process and responsibilities could benefit fromrevision. All 
HMR accredited pharmacists are trained to the same level; 
completion of one of the national accreditation courses. 
Thesearelargely theoretical, based on coursework andthe 
experience level at entry may vary. A minimumof two years 
practiceexperience is required but some entrantshave moreand 
may also have postgraduate qualifications. The assessment is 
also of a traditional style, heavily dependent upon 
demonstrating written knowledge, both in case-based and 
online multi-choice question assessments. There appears to be 
a mismatch between the training and the real-life HMR 
process, where reference to primary evidence sourcesand 
guidelines are used to justify recommendations. It is postulated 
that the missing element in both the training and assessment 
are: 
 
 Oral communication skills; the ability to communicate 
clinical knowledge with doctors and patients. 
 The ability to use devices and demonstrate their use to 
patients. 
 
In a study to evaluate pharmacists’ perceptions of service 
benefits to older people in New Zealand, participants found 
that patients benefit more when medication management 
reviews were combined with other services such as 
international normalised ratio monitoring, point of care testing 
and education. Another study of HMR in chronic disease 
management, indicated that fromall participatingpharmacists’ 
requests to GP’s to initiate a referral for HMR, only 30% were 
actioned and received (Gerrard et al., 2012)). In this study, 
only two GP’stook the time to write back to the pharmacist 
providing feedback on their patients. Both thanked the 
pharmacist for their constructive suggestions and reported 
them to have been implemented. This demonstrates the value 
of two-way communication and underlines the limited value of 
HMR when the communication is only uni-directional. Stone 
and Williams (2015) discuss the importance of the 
development of pharmacists working in general practice in the 
United Kingdom. They discuss the changing emphasis in 
primary healthcare with the challenge of non-communicable 
diseases. Once the diagnosis is made, the challenge is 
maintaining adherence to therapy. To achieve this, new 
approaches will be required and pharmacists working side by 
side with doctors with open communication is seen as integral 
to the model. Gerrard et al. (2012) looked at patient 
preferences in seeing health professionals at their GPpractice. 
They found patients preferred to see their own GP but would 
rather see a pharmacist than an unfamiliar doctor. Primary 
healthcare must change from an acute sickness service to a 
chronic disease adherence support model, focussed on 
achieving the best possible results from ongoing medications. 
This works better in a team approach with effective 
communication between team members. As shown in this 
study, there were examples of excellent practice and good 
communication but there also were many missed opportunities. 
In the busy, time pressured, world of general medical practice, 
a high level of tasks prioritisation is essential. However, it is 
clear from this study that the potential outcomes of this 
publicly-funded intervention are currently compromised. The 
reasons are multifactorial, and may include, but are not limited 
to the following: 
 
 Pharmacists may send the doctor long reports rather 
than a concise report with clear justifiable 
recommendations. 
 They use terminology that may be perceived as 
offensive; such as ‘inappropriate prescribing.’ We do 
not believe any doctor will intentionally to prescribe 
inappropriately. 
 
Doctors may feel that 
 
 They already invested the time and effort to generate 
the referral and that no additional time should be used 
for the same patient without a furthervisit charge. 
 The issues they referred the patient to the pharmacist 
for, can be resolved by the interview alone without 
follow-up actions required of them. 
 The pharmacist’s recommendations were not 
considered sound or based on the full picture of the 
patient history and comorbidities. 
 The reports are filed in the patient record by clinic 
manager without GP review. 
 
These issues are unlikely to be corrected without revision of 
the current HMR process. It requires afinal step offormal 
correspondence from the GP to the pharmacist acknowledging 
receipt of the report, and their intended action to close the care 
cycle. The correspondence should include explanation of the 
reason for dismissing any of the harmacist’srecommendations.  
This should occur before paymentto the pharmacist and GPare 
authorised. It is understood that some of the recommendations 
cannot be actioned, and some will be a matter of opinion, 
however, for patients’ benefit, and the pharmacist’s education, 
clarification is essential. Patients need to know that the time 
spent with thepharmacist at their home was valued and that the 
two parties involved in their carecommunicated on those issues 
together. The process should focus on patients’ outcomes, not 
the income generation process. 
Under the present system, the pharmacist receives no 
remuneration until the doctor reports to Medicare that the 
pharmacist’s report has been received, but the doctor is 
remunerated immediately the referral is sent. A requirement of 
follow-up communication before any remuneration could 
provide a means of closing that loop. A balanced requirement 
that was simple and quick for example, using two on online 
tick boxes for the doctor to acknowledgement 1) receipt of the 
pharmacist report and 2) their intention (to action or not action 
the recommendations). Similar online questions should be 
directed to the pharmacist after the GP complete their section 





This study appears to demonstrate a disconnection in 
communication that adversely affects the continuity of care, 
interdisciplinary input into care andmay compromise 
patients’health outcome. It appears there are four areasthat are 




 The initiation of HMR process: consideration needs to 
be given to enabling pharmacist-initiated HMR, while 
maintaining GPinitiation as an equally important route. 
 Provision of required history and diagnostic 
information prior to the review. This must be an 
expectation on referral by the GPor request by the 
pharmacist for the purpose of a review.It is unrealistic 
to expect a pharmacist to make appropriate 
recommendations without this information. 
 Acknowledgement of receipt of the report by the GP 
should also be a firm obligation. Feedback on the 
actions to be taken should be submitted to Medicare 
with the claim for payment, copied to the pharmacist. 
 Discussion and/or action of recommendations. This 
should be an expectation and actively encouraged. 
 HMR is a potentially valuable service but some fine-
tuning of the process is required, if it is to deliver value 
for money and positive outcomes. 
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